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Introduction
Over the years, there have been scattered, sporadic (and 
usually small) studies on Toxoplasma gondii seroprevalence 
in the African continent, and this is unfortunate. The current 
human immunodeficiency virus (HIV) epidemic on the 
continent, increasing levels of other immunosuppressive 
infections (such as tuberculosis), poor sanitation and hygiene 
practices, inadequate veterinary services, and high levels of 
poverty, coupled with lack of proactive monitoring of at-risk 
populations and reporting of these investigations, is part 
of the challenge. The absence of public health schemes 
to manage the spread of this pathogen places African 
populations at risk of ongoing and possibly increasing 
incidence and prevalence, as well as a corresponding 
increase in mortality and morbidity due to toxoplasmosis. 
This may be the case in particular for toxoplasma 
encephalitis, which is currently a leading cause of mortality 
and morbidity in HIV patients who have progressed to full 
blown acquired immune deficiency syndrome, (AIDS) who 
and are not on highly active antiretroviral therapy in Africa.1
There have been few studies on seroprevalence rates of 
T. gondii in animal species on the African continent. Given 
the large numbers of domestic and wild animals in Africa, as 
well as the lack of sophisticated animal husbandry, there is 
a high likelihood of transmission and hence mobility of the 
pathogen from animal hosts to human hosts, together with 
an increased risk of morbidity and mortality. 
Method
A literature search of the National Centre for Biotechnology 
Information, Pubmed, Google Scholar and ToxoDB 
databases was performed, with the keywords “Toxoplasma 
gondii seroprevalence studies in Africa”. This was 
then followed by another search using the keywords 
“toxoplasmosis in Africa”. A further search was carried 
out on the references of the selected publications, as well 
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as on infectious diseases congress reports and abstract 
compilations. Publications were selected using the year end 
2012 as a cut-off.
Confidence intervals pertaining to seroprevalence rates for 
each reported study were derived from the corresponding 
publication, where available.
Results
Monitoring and reporting on T. gondii seroprevalence in 
Africa has been less than adequate since the first report 
was published in 1971. Figure 1 depicts the number of 
T. gondii seroprevalence studies conducted in both human 
and animal cohorts in Africa up until 2012. The first reported 
study was in 1971. The highest number of studies reported 
in the literature was between 1991 and 2000, and 2001 and 
2011, for both human and animal cohorts.
The seroprevalence surveys that were conducted did not 
focus on comparable cohorts over time. Therefore, caution 
needs to be exercised when interpreting the data. The data 
presented in Tables I, II and III (and Table IV for animals), 
classify the investigations according to the locations in 
which they were conducted, the sample size of the study, 
the year in which the study was conducted in chronological 
order, the level of seroprevalence as a percentage, as well 
as the type of population investigated.
Discussion
Toxoplasmosis in immunocompetent individuals 
Studies on T. gondii in asymptomatic individuals in 
Africa are limited in number, and none of the countries 
follow a systematic planned pattern of reporting (Table 
I). Seroprevalence rates range from 6.4-74.5%, with a 
median of 37%. The first reported study was from South 
Africa, by Mason, Jacobs and Fripp2 in 1974, whereby a 
seroprevalence of 20% was found in a cohort comprising 
black, white, Indian and coloured immunocompetent 
individuals. Since then, other studies, the most recent being 
Kistiah et al,18 have reported a 6.4% seroprevalence in a 
generalised cohort, but it was biased towards pregnant 
women. Swai and Schoonman16 reported seroprevalence 
of 45.7% in a Tanzanian cohort predominantly comprising 
immunocompetent individuals who were exposed to 
livestock via their occupation (abattoir workers, livestock 
keepers and animal health workers). Zumla et al6 reported 
seroprevalence of 27% in Uganda, while Griffin and Williams5 
reported seroprevalence of 42% in Kenya. Further north, 
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Figure 1: Number of seroprevalence studies per decade [1971-1980, 
1981-1990, 1991-2000, 2001-2010 and 2011- 2012 (incomplete 
decade)]
Table I: Toxoplasma gondii seroprevalence studies in immunocompetent individuals in Africa (human)
References Country (region) Sample size 
(absolute numbers)
Seroprevalence % 
(95% CI)
Year
Mason, Jacobs and Fripp2 South Africa (Transvaal) 806 37 1974
Jacobs and Mason3 South Africa (nationwide) 3 379 20 1978
Zardi, Adorisio, Harare and Nuti4 Somalia 356 43 1980
Griffin and Williams5 Kenya 322 42 1983
Zumla et al6 Zambia 189 11 1991
Zumla et al6 Uganda 93 27 1991
Abdel-Hameed7 Sudan (Gazira) 368 41.7 1991
Giebre-Xabier et al8 Ethiopia (nationwide) 1 016 74.4 1993
Julvez et al9 Niger (Niamey) 371 18 1996
Bouratbine et al10 Tunisia 564 58.4 2001
Maïga, Kiemtoré and Tounkara11 Mali (Bamako) 21 2001
Hussein et al12 Egypt (Qualyobia) 152 57.9 2001
Uneke, Duhlinska, Njoku and Ngwu13 Nigeria 144 20.8 2005
Fan et al14 Sao Tome and Principe (nationwide) 161 74.5 2007
Elsheikha et al15 Egypt 260 59.6 2009
Swai and Schoonman16 Tanzania (Tanga) 199 45.7 2009
Sellami et al17 Tunisia (Sfax) 1 691 13.7 2010
Kistiah et al18 South Africa (Gauteng) 497 6.4 2011
Ouologuem et al19 Mali (Kolle) 760 27 2012
CI: confidence interval
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Abdel-Hameed7 reported a seroprevalence rate of 41.7% 
in Sudan, while Elsheikha et al15 and Bouratbine et al10 
reported seroprevalence of 59.6% and 58.4%, in Egypt and 
Tunisia, respectively. The highest seroprevalence reported 
in the west of Africa was 74.5% by Fan et al14 in Sao Tome 
and Principe, and the lowest of 20.8% by Uneke, Duhlinska, 
Njoku and Ngwu13 in Nigeria. Prevalence rates in northern 
Africa followed a decreasing trend over time from 58.4% 
in 2001 to 13.7% in 2010. There was also a decreasing 
trend from 37% in 1974 to 6.4% in 2011 in southern Africa, 
and an increasing trend from 21% in 2001 to 27% in 2012 
in western Africa. There was also an increasing trend in 
Eastern Africa from 43% in 1980 to 45.7% in 2009.
Women of reproductive age and pregnant women 
A number of studies have been conducted on the risk group 
of women of reproductive age and pregnant women. Most of 
the studies were carried out in the west and north of Africa. 
The south and the east are under-represented in studies 
(Table II). Seroprevalence rates range from 12.8% to 83.5%, 
with a median of 42.5%. High rates of seroprevalence have 
been reported in the west of Africa, where Ndumbe et al22 
reported prevalence of 77.1% in Cameroon, and Hung 
et al35 75.2% prevalence in Sao Tome and Principe. The 
highest rate on the continent was recorded in the southern 
part of Madagascar by Lelong et al,27 where seroprevalence 
of 83.5% was reported. The lowest seroprevalence was 
reported in South Africa, when Kistiah et al18 reported 
prevalence of 12.8%. Seroprevalence rates in North Africa 
have generally been high, with the highest being 58.1% in 
Egypt, reported by Hussein et al.12
Seroprevalence rates in northern Africa showed a 
decreasing trend over time from 58.1% in 2001 to 39.3% in 
2012. There was an increasing trend in southern Africa from 
3% in 1975 to 12.8% in 2011, while there was an increasing 
trend in seroprevalence from 70% in 1989 to 75% in 2007 
in western Africa. Seroprevalence rates are generally high 
in women of reproductive age. It is interesting to note that 
such high levels are comparable to those reported in similar 
South American cohorts.58 
Human immunodeficiency virus- and acquired immune 
deficiency syndrome-related toxoplasmosis 
With the advent of the HIV-AIDS era, the significance of 
toxoplasmosis was realised, resulting in an increase in 
the number of seroprevalence investigations, particularly 
in HIV-positive, compared to HIV-negative, populations 
(Table III). Seroprevalence rates range from 4-80%, with a 
median of 36.35%. The highest seroprevalence of T. gondii 
Table II: Toxoplasma gondii seroprevalence studies in women of reproductive age in Africa (human)
References Country (region) Sample size (absolute 
numbers)
Seroprevalence % 
(95% CI)
Year 
Brink, de Wet and van Rensburg20 South Africa (Bloemfontein) 600 3 1975
Dumas et al21 Ivory Coast > 2 000 37.2-70 1989
Ndumbe et al22 Cameroon (Yaounde) 192 77.1 1992
Schneider, Schutte and Bommer23 South Africa (KwaZulu-Natal) 31.3 1992
Faye et al24 Senegal (Dakar) 353 40.2 1993
Diallo et al25 Senegal (Dakar) 720 40.3 1993
Rodier et al26 Benin (Coutonou) 211 53.6 1995
Lelong et al27 Madagascar (Antanavario) 599 83.5 1995
Doehring et al28 Tanzania (Dar es Salaam) 849 35 1995
Onadeko, Joynson, Payne and Francis29 Nigeria 75.4 1996
Nabias et al30 Gabon (Franceville) 767 71.2 1998
Hussein et al12 Egypt (Qualyobia) 31 58.1 2001
Hussein et al12 Egypt (Qualyobia) 38 44.7 2001
Elnahas et al31 Sudan (Khartoum and Omdurman) 487 34.1 2003
Adou-Bryn et al32 Ivory Coast (Yopougon) 1 025 60 2004
Simpore et al33 Burkina Faso (Ougadougou) 336 25.3 2006
El Mansouri et al34 Morroco (Rabat) 2 456 50.6 2007
Hung et al35 Sao Tome and Principe (nationwide) 499 75.2 2007
Ghoneim et al36 Egypt (El Fayoum) 68 20.45 2009
Ghoneim et al36 Egypt (El Fayoum) 20 17.9 2009
Sellami et al17 Tunisia (Sfax) 40 566 39.3 2012
Kistiah et al18 South Africa (Gauteng) 376 12.8 2011
CI: confidence interval
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Table III: Toxoplasma gondii seroprevalence studies in individuals with human immunodeficiency virus and acquired immune deficiency syndrome in 
Africa (human)
References Country (region) Sample size (absolute 
numbers)
Seroprevalence % 
(95% CI)
Year
Zumla et al6 Zambia 187 4 1991
Zumla et al6 Uganda 186 34 1991
Brindle, Holliman, Gilks and Waiyaki37 Kenya (Nairobi) 94 54 1991
Lucas et al38 Ivory Coast 294 21 1993
Ledru et al39 Burkina Faso 45 55.5 1995
Ledru et al39 Burkina Faso 50 52 1995
Ledru et al39 Burkina Faso 40 62.5 1995
Arenas et al40 South Africa 
(Western Cape)
327 43 1995
Arenas et al40 South Africa 
(Western Cape)
91 26 1995
Arenas et al40 South Africa 
(Western Cape)
61 15 1995
Woldemichael et al41 Ethiopia (Addis Ababa) 170 80 1998
Sonnenberg, Silber and Jentsch42 South Africa (KwaZulu-Natal) 24.6 1998
Millogo et al43 Burkina Faso (Bobo-Dioulasso) 1 828 25.4 2000
Maïga, Kiemtoré and Tounkara11 Mali (Bamako) 60 2001
Uneke, Duhlinska, Njoku and Ngwu13 Nigeria 219 38.8 2005
Lindström et al1 Uganda (Malago) 130 54 2006
Hari, Modi, Mochan and Modi44 South Africa (Gauteng) 307 8 2007
Sitoe et al45 Mozambique 150 18.7 2010
Sellami et al17 Tunisia (Sfax) 78 11.7 2010
Akanmu, Osunkalu, Ofomah and 
Olowoselu46
Nigeria (Lagos) 380 54 2010
Besong and Mathomu47 South Africa (north eastern) 160 18.1 2010
Kistiah et al18 South Africa (Gauteng) 376 9.8 2011
Addebbous et al48 Morroco (Marrakesh) 95 62.1 2012
Ogina, Onyemelukwe, Musa and 
Obiako49
Nigeria (northern) 219 38.7 2013
CI: confidence interval
Table IV: Toxoplasma gondii seroprevalence studies in Africa (animals)
References Country (region) Sample size (absolute 
numbers)
Seroprevalence % 
(95% CI)
Year
Cheadle, Spencer and Byron50 South Africa (various) 68 74 1999
Van der Puije et al51 Ghana (nationwide) 732 33.2 2000
Van der Puije et al51 Ghana (nationwide) 526 26.8 2000
Penzhorn et al52 Botwana (Chobe) 53 92 2002
Penzhorn et al52 Namibia (Windhoek) 21 100 2002
Penzhorn et al52 South Africa 
(Kruger Park)
12 100 2002
Penzhorn et al52 South Africa (Hluhluwe-imfolozi Park) 30 100 2002
Penzhorn et al52 Botwana (Chobe) 1 100 2002
Penzhorn et al52 South Africa (Kruger Park) 7 86 2002
Hove, Lind and Mukaratirwa53 Zimbabwe (nationwide) 335 67.9 2005
Samra, McCrindle, Penzhorn and 
Cenci-Goga54
South Africa (nationwide) 600 4.3 2007
Dubey et al55 Ghana (Kumasi) 64 64.1 2008
Ghoneim et al36 Egypt (El Fayoum) 62 98.4 2009
Ghoneim et al36 Egypt (El Fayoum) 24 41.7 2009
Boughattas et al56 Tunisia (nationwide) 158 17.7 2011
CI: confidence interval
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in HIV patients was reported in Ethiopia by Woldemichael 
et al,41 with 80% seroprevalence in 170 patients tested. 
The average seroprevalence figure was 52% in west Africa, 
ranging from 62.5% in Burkina Faso, to 21% in Ivory Coast, 
by Ledru et al39 and Lucas et al,38 respectively. The lowest 
rate on the continent, 4%, was recorded in Zambia by Zumla 
et al.6 Lindström et al1 and Brindle, Holliman, Gilks and 
Waiyaki37 reported seroprevalence rates of 54% in Uganda 
and Kenya, respectively. Only one study was reported from 
the north of Africa. It was by Addebbous et al48 in Morocco, 
where a seroprevalence rate of 62.5% was provided. 
Seroprevalence studies in the southern part of Africa have 
mostly derived from South Africa. Sonnenberg, Silber 
and Jentsch42 reported the highest seroprevalence rate of 
24.6% in KwaZulu-Natal province. The lowest rate of 8% 
was reported in Gauteng province by Hari, Modi, Mochan 
and Modi.44Seroprevalence rates follow an increasing trend 
in northern Africa from 11.7% in 2010 to 62.1% in 2012. 
There was also an increasing trend in southern Africa from 
4% in 1991 to 9.8% in 2011, in western Africa of 21% in 
1993 to 38.2% in 2013, and in eastern Africa from 34% in 
1991 to 54% in 2006. 
Toxoplasmosis in animal species
Most of the studies reported to date have been carried 
out in the southern part of Africa (Table IV) where Samra, 
McCrindle, Penzhorn and Cenci-Goga54 demonstrated 
seroprevalence of 4.5% in a 600 sheep cohort in South 
Africa. In Zimbabwe, Hove, Lind and Mukaratirwa53 
reported seroprevalence of 67.9% in 335 investigated 
sheep and goats. Cheadle, Spencer and Byron50 reported 
seroprevalence of 74% in wild felids in South Africa, and 
Penzhorn et al52 seroprevalence of 100% in lions from the 
Kruger National Park and Hluhluwe-imfolozi Park in South 
Africa, and 92% in lions from Botswana (Chobe National 
Park). T. gondii antibodies have also been detected in 
felids in the wild, and in chinchillas, ferrets, cheetah, a dog 
and leopards in southern Africa. In Ghana, Dubey et al55 
reported seroprevalence of 64.1% in free-range chickens, 
while seroprevalence of 38.2% in sheep, and 26.8% in 
goats, respectively, was reported by Van der Puije et al.51 
There have been no documented reports on seroprevalence 
in animals from the eastern part of Africa, but in Egypt, 
Ghoneim et al36 reported seroprevalence of 98.4% in 
sheep. Reported seroprevalence rates range from 4.3% to 
100%, with a median of 74%. Seroprevalence rates show a 
decreasing trend over time in northern Africa from 98.4% in 
2009 to 17.7% in 2011. There was also a decreasing trend 
from 74% in 1999 to 43% in 2007 in southern Africa, and 
an increasing trend in western Africa from 33.2% in 2000 to 
64.1% in 2008. 
Conclusion
Overall, seroprevalence rates on the continent are very high 
in both human and animal populations. The data suggest 
a geographical trend, with decreasing seroprevalence from 
the northern to the southern, and from the western to the 
eastern, regions of the continent. Most seroprevalence 
studies on humans were reported between 1981 and 
2000. The majority of the serosurveys were carried out 
on immunocompetent individuals, followed by women of 
reproductive age, and then on HIV/AID patients. Only a 
limited number of these studies took into consideration 
risk factors that are most important for infection with the 
pathogen. Thus, very few surveys have been performed 
with regard to animals in order to understand zoonotic 
risk. If risk factors from studies in other parts of the world 
are taken into account, it is possible to infer that large 
numbers of people on the African continent, such as 
pregnant women and HIV-positive individuals, are at risk 
of a primary infection or reactivation of a chronic infection. 
Seroprevalence rates generally demonstrated decreasing 
trends over time in northern, southern and eastern Africa in 
all the groups studied. A noteworthy exception was western 
Africa, where seroprevalence rates showed an increasing 
trend over time in all the groups, and in HIV-AIDS patient 
cohorts where prevalence rates showed an increasing 
trend over time in all the regions. These data suggest that 
overall seroprevalence rates follow an increasing gradient 
from relatively low prevalence in the southern part of the 
continent, to moderate to high in the west and east, and 
highest in the northern part of Africa. These findings must 
be taken seriously, and further structured investigations 
carried out to ascertain the causative factors and action 
required to mitigate their effects.
This information is important because even if only 5% 
of individuals are infected and present with clinical 
manifestations, the implications for the burden of disease 
in Africa, with a population approaching one billion, are 
staggering. Given that toxoplasmosis is associated with 
clinical manifestation in HIV-positive individuals, and given 
that reactivation of a latent infection can be life-threatening58 
owing to a number of factors, including increased 
immunosuppression and encephalitis,49 it is possible that 
this disease may be a neglected driver for clinical diseases 
such as tuberculosis, or other chronic or infectious illnesses 
that might otherwise not manifest themselves. In this case, 
the burden of disease and disability-adjusted life year cost 
to Africa from toxoplasmosis is considerable and deserves 
attention.
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